ArticleThe Journal of pathology2022
Benign prostatic hyperplasia/obstruction ameliorated using a soluble guanylate cyclase activator.
Article in The Journal of pathology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 29 citations in OpenAlex.
- Global stagnation and misaligned priorities in BPH drug development: a 25-year landscape analysis of clinical trial registries.npj aging · 2026Article
- Endogenous vasopressin and vasopressin receptor 2 in bladder as anti-diuretic / anti-spasmodic targets for the treatment of multifactorial nocturia.Continence (Amsterdam, Netherlands) · 2025Article
- Induction of chronic prostatitis does not alter the innate contractile properties of the prostate or urethra in rats.Scientific reports · 2025Article
- Pharmacological activation of NO-sensitive guanylyl cyclase ameliorates obesity-induced arterial stiffness.Vascular pharmacology · 2025Article
- Discovery of Lignans from the Herbs ofMolecules (Basel, Switzerland) · 2025Article
- Can the Bladder Itself "Measure" Volume, and Thereby Help to Determine When Initiation of Voiding Should Occur? ICI-RS 2024.Neurourology and urodynamics · 2025Review
- New therapeutic targets to prevent benign prostatic enlargement and symptomatic progression to benign prostatic obstruction-ICI-RS 2023.Neurourology and urodynamics · 2024Review
- What do we really know about the external urethral sphincter?Continence (Amsterdam, Netherlands) · 2024Review
- Unraveling the complexity of bladder-centric chronic pain by intravesical contrast enhanced MRI.Continence (Amsterdam, Netherlands) · 2023Article
- Soluble Guanylate Cyclase Activators to Treat Benign Prostatic Hyperplasia and associated LUTS.Continence (Amsterdam, Netherlands) · 2023Article
- Treating Lower Urinary Tract Symptoms in Older Adults: Intravesical Options.Drugs & aging · 2023Review
- Understanding human aging and the fundamental cell signaling link in age-related diseases: the middle-aging hypovascularity hypoxia hypothesis.Frontiers in aging · 2023Article
- Soluble guanylate cyclase mediates the relaxation of healthy and inflamed bladder smooth muscle by aqueous nitric oxide.Frontiers in physiology · 2023Article
- Oxidative Stress and Its Relation to Lower Urinary Tract Symptoms.International neurourology journal · 2022Article
- E-cadherin deficiency promotes prostate macrophage inflammation and bladder overactivity in aged male mice.Aging · 2022Article
- Bibliometric study of soluble guanylate cyclase stimulators in cardiovascular research based on web of science from 1992 to 2021.Frontiers in pharmacology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 4 institutions in 4 countries.
Funding
Abstract
Benign prostatic hyperplasia (BPH) is a feature of ageing males. Up to half demonstrate bladder outlet obstruction (BOO) with associated lower urinary tract symptoms (LUTS) including bladder overactivity. Current therapies to reduce obstruction, such as α1-adrenoceptor antagonists and 5α-reductase inhibitors, are not effective in all patients. The phosphodiesterase-5 inhibitor (PDE5I) tadalafil is also approved to treat BPH and LUTS, suggesting a role for nitric oxide (NO
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.